Recently, the United States (US) Food and Drug Administration (FDA) has approved a novel treatment for generalized myasthenia gravis (MG).¹ Efgartigimod is the first of a new class of medication for this rare autoimmune neuromuscular disease.¹ Recent finding published in the Lancet Neurology suggested that the safety, efficacy and tolerability of efgartigimod were more favorable in treating generalized MG patients than the existing therapies.²

Migraine is a neurological disease caused by the release of inflammatory substances in the brain that triggers headache.¹ There is an unmet need to develop suitable treatment options for migraine patients with aura.² Recently, the use of erenumab, the first-in-class anti-calcitonin gene-related peptide (CGRP) monoclonal antibody, has demonstrated significant reduction in migraine frequency and improved safety in patients with migraine.^2,3